Abstract：Objective To study the safety and efficacy of Zhengqiang Fengtongning Tablets in the treatment of IgA nephropathy with moderate amount of proteinuria. Methods 156 patients with IgA nephropathy with moderate amount of proteinuria (urine protein quantitation: 1-3 g/24 h) were randomly divided into two groups. The study group was given Zhengqiang Fengtongning Tablets with valsartan and control group was given valsartan alone for treatment. The dosage of Zhengqiang Fengtongning was 2 tablets, 3 times a day, and valsartan was 80 mg/day. Results After treatment for 6 months, the total effective rate in the study group was significantly higher than that in the control group( 87.2% vs 56.4%, P＜0.01). 24 h urinary protein in the study group was significantly lower than that in the control group(1.59±0.66, P＜0.05). There were no differences in serum albumine, serum creatinine (Scr) , total protein (TP), total cholesterol (TC), and incidence of adverse reactions between the two groups. Conclusions Zhengqiang Fengtongning Tablets combined with valsartan for the treatment of IgA nephropathy with moderate amount of proteinuria is safe and reliable, which is worthy of clinical application.
王文,高德,祖静,贺晓. 正清风痛宁片治疗IgA肾病中等量蛋白尿的疗效[J]. 武警医学, 2014, 25(10): 1021-1023.
WANG Wen, GAO De, ZHU Jing, HE Xiao. Efficacy of Zhengqiang Fengtongning Tablets in the treatment of IgA nephropathy with moderate amount of proteinuria. Med. J. Chin. Peop. Armed Poli. Forc., 2014, 25(10): 1021-1023.
Lee H S, Lee M S, Lee S M, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system[J]. Nephrol Dial Transplant, 2005, 20(2):342-348.
[3]
Samuels J A, Strippoli G F, Graig J C ,et al. Immunosuppressive treatments for immunoglobulin a nephropathy: a meta-analysis of randomized controlled trials[J]. Nephrology ,2004,9(4):177-185.
[8]
Yang Y,Ohta K,Shimizu M,et al.Treatment with low-dose angiotensin-converting enzyme inhibitor(ACEI) plus angiotensin Ⅱ receptor blocker(ARB)in pediatrics patients with IgA nephrology[J].Clin Nephrol,2005,64(1):35-40.
Cheng Y,Zhang J,Hou W,et al.Immunoregulatoy effects of sinomenine on the T-bet/GATA-3 ratio and Th1/ Th2 cytokine balance in the treatment of mesangial proliferative nephritis[J].Int J Immunopharmacol,2009,9(7):894-899.
Lee H S, Lee M S, Lee S M, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system[J]. Nephrol Dial Transplant, 2005, 20(2):342-348.
Yang Y,Ohta K,Shimizu M,et al.Treatment with low-dose angiotensin-converting enzyme inhibitor(ACEI) plus angiotensin Ⅱ receptor blocker(ARB)in pediatrics patients with IgA nephrology[J].Clin Nephrol,2005,64(1):35-40.
Cheng Y,Zhang J,Hou W,et al.Immunoregulatoy effects of sinomenine on the T-bet/GATA-3 ratio and Th1/ Th2 cytokine balance in the treatment of mesangial proliferative nephritis[J].Int J Immunopharmacol,2009,9(7):894-899.
2014, Vol. 25 
